Roxadustat Ameliorates Thoracic Aortic Dissection by Activating HIF‐1α‐Mediated Mitophagy to Inhibit Ferroptosis
The FASEB Journal · 2026
DOI: 10.1096/fj.202600149r ↗Kurz gefasst
Fachartikel in der Zeitschrift The FASEB Journal, 2026. Verfasst von Dan Zhao und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiovascular Surgery, The First Affiliated Hospital of Henan University, Henan University, Kaifeng, China. Hauptthemen laut MEDLINE: Hypoxia-Inducible Factor 1, alpha Subunit, Mitophagy, Ferroptosis, Glycine. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 54 Literaturangaben. Gefördert von: MOST | National Natural Science Foundation of China (NSFC), Provincal and Departmental Joint Construction of Medical Science and Technology Innovation in Henan Province, Medical Science and Technology Innovation in Kaifeng City.
Abstract (Originalsprache)
Thoracic aortic dissection (TAD) is a life‐threatening cardiovascular disease with limited pharmacological treatments. Vascular smooth muscle cell (VSMC) loss is a critical pathological feature of TAD. Roxadustat (ROX), a HIF stabilizer for renal anemia, was evaluated in a β‐aminopropionitrile (BAPN)‐induced TAD mouse model. It significantly improved survival, attenuated weight loss and aortic dilation, decreased the incidence of TAD, alleviated elastic fibers damage, and ultimately inhibited TAD progression. Mechanistically, ROX upregulated HIF‐1α expression, reduced vascular wall iron deposition and lipid peroxidation products (MDA, 4‐HNE), and normalized aberrant expression of ferroptosis markers ACSL4, TFR1, GPX4 and FTH1. In vitro, it mitigated Erastin/Ang II‐induced VSMC ferroptosis, improved mitochondrial structure and function by enhancing oxygen consumption rate (OCR), restoring membrane potential, reducing reactive oxygen species (ROS), and boosting mitophagy via upregulating HIF‐1α and mitophagy markers (PINK1, Parkin). The HIF‐1α inhibitor KC7F2 and siHIF‐1α reversed these effects. Taken together, our findings demonstrate that ROX protects against TAD by promoting HIF‐1α expression to enhance mitophagy and inhibit VSMC ferroptosis, offering potential clinical implications for TAD prevention and treatment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Cardiovascular Surgery, The First Affiliated Hospital of Henan University, Henan University, Kaifeng, China.
- Cardiovascular Medicine, Xinxiang Central Hospital, Xinxiang, China.
- Joint National Laboratory for Antibody Drug Engineering, Henan University, Kaifeng, China.
- Pharmaceutical Department, The First Affiliated Hospital of Henan University, Henan University, Kaifeng, China.
- School of Basic Medical Sciences, Henan University, Kaifeng, China.
ORCID-Profile: Ziqi Chang, Yaohui Wang
Förderung
- MOST | National Natural Science Foundation of China (NSFC)
- Provincal and Departmental Joint Construction of Medical Science and Technology Innovation in Henan Province
- Medical Science and Technology Innovation in Kaifeng City
- National Natural Science Foundation of China
Zitieren
APA
Zhao, D., Chang, Z., Han, Q., Wang, Q., Zhai, Y., Sun, M., Cai, D., Zhang, L., Zheng, X., & Wang, Y. (2026). Roxadustat Ameliorates Thoracic Aortic Dissection by Activating HIF‐1α‐Mediated Mitophagy to Inhibit Ferroptosis. The FASEB Journal. https://doi.org/10.1096/fj.202600149r
Vancouver
Zhao D, Chang Z, Han Q, Wang Q, Zhai Y, Sun M, et al. Roxadustat Ameliorates Thoracic Aortic Dissection by Activating HIF‐1α‐Mediated Mitophagy to Inhibit Ferroptosis. The FASEB Journal. 2026. doi:10.1096/fj.202600149r
BibTeX
@article{Zhao2026,
author = {Zhao, Dan and Chang, Ziqi and Han, Qiong and Wang, Qiaoyu and Zhai, Yan and Sun, Mingfei and Cai, Dengta and Zhang, Lijie and Zheng, Xianjie and Wang, Yaohui},
title = {Roxadustat Ameliorates Thoracic Aortic Dissection by Activating HIF‐1α‐Mediated Mitophagy to Inhibit Ferroptosis},
journal = {The FASEB Journal},
year = {2026},
doi = {10.1096/fj.202600149r}
}
EUVIMED